Overview of Efalizumab Open-label Trials

An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.